Novartis AG ADR (NVS)vsVSee Health, Inc. (VSEE)
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
VSEE
VSee Health, Inc.
$0.16
-3.64%
HEALTHCARE · Cap: $7.13M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 391256% more annual revenue ($56.58B vs $14.46M). NVS leads profitability with a 23.9% profit margin vs -92.4%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
VSEE
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for VSEE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -258.8% — below average capital efficiency
Revenue declined 4.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : VSEE
The strongest argument for VSEE centers on Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : VSEE
The primary concerns for VSEE are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while VSEE is a turnaround play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 28/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →VSee Health, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
VSee Health, Inc. is a pioneering leader in the telehealth industry, delivering secure and intuitive video communication solutions specifically designed for healthcare professionals and patients. The company's versatile platform features essential functionalities, including remote patient monitoring, asynchronous messaging, and robust electronic medical record (EMR) interoperability, aimed at improving healthcare delivery efficiency and quality across diverse medical specialties. By prioritizing patient engagement and accessibility, VSee serves a broad international client base, strategically positioning itself to leverage the increasing demand for virtual care in the transforming healthcare landscape. With a focus on innovation and customer success, VSee Health is well-equipped for substantial growth as digital healthcare solutions become increasingly critical.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?